特立氟米特致多发性硬化患者盘状红斑狼疮1例报告

IF 2.4 4区医学 Q2 RHEUMATOLOGY

International Journal of Rheumatic Diseases Pub Date : 2025-05-25 DOI:10.1111/1756-185X.70300

Fereydun Moradi, Kaveh Bahrami, Mohammadali Nahayati

{"title":"特立氟米特致多发性硬化患者盘状红斑狼疮1例报告","authors":"Fereydun Moradi, Kaveh Bahrami, Mohammadali Nahayati","doi":"10.1111/1756-185X.70300","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Teriflunomide is an immunomodulatory drug commonly used in the treatment of multiple sclerosis (MS). While generally well-tolerated, it can sometimes lead to adverse effects, including various forms of drug-induced lupus. Discoid Lupus Erythematosus (DLE) is a chronic dermatological condition characterized by erythematous, scaly plaques, primarily affecting the face and scalp. There are limited reports of DLE induced by Teriflunomide, making it an area of clinical interest.</p>\n </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discoid Lupus Erythematosus Induced by Teriflunomide in a Patient With Multiple Sclerosis: A Case Report\",\"authors\":\"Fereydun Moradi, Kaveh Bahrami, Mohammadali Nahayati\",\"doi\":\"10.1111/1756-185X.70300\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Teriflunomide is an immunomodulatory drug commonly used in the treatment of multiple sclerosis (MS). While generally well-tolerated, it can sometimes lead to adverse effects, including various forms of drug-induced lupus. Discoid Lupus Erythematosus (DLE) is a chronic dermatological condition characterized by erythematous, scaly plaques, primarily affecting the face and scalp. There are limited reports of DLE induced by Teriflunomide, making it an area of clinical interest.</p>\\n </div>\",\"PeriodicalId\":14330,\"journal\":{\"name\":\"International Journal of Rheumatic Diseases\",\"volume\":\"28 5\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-05-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Rheumatic Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70300\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70300","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

特立氟米特是一种免疫调节药物，通常用于治疗多发性硬化症（MS）。虽然通常耐受性良好，但有时会导致副作用，包括各种形式的药物性狼疮。盘状红斑狼疮（DLE）是一种以红斑、鳞状斑块为特征的慢性皮肤病，主要影响面部和头皮。特立氟米特引起DLE的报道有限，使其成为临床关注的领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Discoid Lupus Erythematosus Induced by Teriflunomide in a Patient With Multiple Sclerosis: A Case Report

Teriflunomide is an immunomodulatory drug commonly used in the treatment of multiple sclerosis (MS). While generally well-tolerated, it can sometimes lead to adverse effects, including various forms of drug-induced lupus. Discoid Lupus Erythematosus (DLE) is a chronic dermatological condition characterized by erythematous, scaly plaques, primarily affecting the face and scalp. There are limited reports of DLE induced by Teriflunomide, making it an area of clinical interest.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Rheumatic Diseases RHEUMATOLOGY-

CiteScore

3.70

自引率

4.00%

发文量

362

审稿时长

1 months

期刊介绍： The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.